Bisphosphonate-related osteonecrosis of the jaw in a chronic hemodialysis patient.
Bisphosphonate-related osteonecrosis of the jaw in a chronic hemodialysis patient. Saudi J Kidney Dis Transpl. 2018 Jan-Feb;29(1):223-224 Authors: Yilmaz SG, Yılmaz F PMID: 29456237 [PubMed - in process]
In the setting of Cardiogenic Shock (CS), impaired biventricular function can lead to an acute decrease in renal function via reduced renal perfusion and increased renal venous pressure. In a nationally representative sample, we sought to analyze the characteristics and outcomes of patients hospitalized with CS requiring renal replacement therapy (hemodialysis) for acute kidney injury (AKI-HD).
Although renal function may improve after left ventricular assist devices (LVAD) implantation, acute kidney injury (AKI) requiring hemodialysis (HD) therapy can occur post-operatively. We sought to investigate in-hospital outcomes and readmissions among patients who developed AKI requiring HD during index admission for LVAD implantation.
Kidney transplantation is the best treatment for patients with end-stage renal disease (ESRD) because of a significant survival benefit conferred compared to patients who remain on haemodialysis.1 Although the prevalence of hepatitis B virus (HBV) and hepatitis C virus (HCV) infection in patients with ESRD has significantly declined over time, it remains at least 4-times higher than in the general population.2,3 Chronic HCV or HBV infection can result in chronic liver disease, cirrhosis, and hepatocellular carcinoma4 –6 and increase the risk of chronic kidney disease (CKD).
Publication date: January 2019Source: Advances in Chronic Kidney Disease, Volume 26, Issue 1Author(s): Vivek Soi, Chantale Daifi, Jerry Yee, Elizabeth AdamsAn in-depth understanding of viral hepatitis is important to the care of patients with end-stage renal disease undergoing hemodialysis. Both hepatitis B and C viruses are acquired through hematogenous spread and can lead to horizontal transmission. Concurrent hepatic and renal injuries have ominous outcomes with significant morbidity. Hepatitis B incidence has decreased through practices including vaccination of nonimmune individuals and isolation of patients with the d...
Publication date: January 2019Source: Advances in Chronic Kidney Disease, Volume 26, Issue 1Author(s): Lizbeth J. Cahuayme-Zuniga, Karen B. BrustPatients with chronic kidney disease have impaired immunity that increases their risk of infection. Increased incidence of mycobacterial infections, in particular Mycobacterium tuberculosis, is described in patients undergoing hemodialysis and peritoneal dialysis as well as after kidney transplantation in low-prevalence and high-prevalence settings. Diagnosis of this infection can be challenging because of atypical presentations that may lead to treatment delay and, consequently, ...
CONCLUSIONSurgical procedures for weight reduction in dialysis patients does not independently increase the risk for adverse outcomes after bariatric surgery. The estimation of DW through BIA is an effective method for avoiding complications generated by excessive or deficient ultrafiltration.
Renal allograft thrombosis is the most frequent and devastating complication in the early postrenal transplantation period. Several risk factors to develop graft thrombosis depending on donors and recipients are well known. Antiphospholipid syndrome (APS) is well recognized as an important cause of kidney injury, with specific clinical and histological features that may lead to renal injury caused by thrombosis at any location within the renal vasculature. There are 3 forms of APS, primary (the most common form), associated to other systemic autoimmune diseases (SAD-APS), and catastrophic. Nevertheless, patients with SAD-A...
Conclusion: A faster RRF decline in the first year was a predictor for all-cause mortality and conversion to HD in non-diabetic PD patients, mainly in the first three year. For patients with faster RRF decline, increasing PD dose was effective to improve survival.Kidney Blood Press Res 2019;44:12 –21
Forty million people in Western Europe have chronic kidney disease (CKD).1 The number of patients receiving renal replacement therapy (RRT) increased by 23% from 2006 to 2015.2,3 Males predominate on dialysis. The mean age of patients receiving dialysis is 61.3 years, and 19% are over 80 years.3 Hemodialysis and transplantation predominate, costing around €40,000 to €80,000 and €10,000 to €20,000 per patient per year, respectively.1 Overall, 2% of health expenditure is consumed by RRT for 0.1% of the population.
Vadadustat is a potential new treatment for anemia in chronic kidney disease -- but what do we know about its impacts in patients receiving hemodialysis?Nephrology Dialysis Transplantation